Literature DB >> 20878842

Seeking informed consent to Phase I cancer clinical trials: identifying oncologists' communication strategies.

Richard Brown1, Carma L Bylund, Laura A Siminoff, Susan F Slovin.   

Abstract

PURPOSE: Phase I clinical trials are the gateway to effective new cancer treatments. Many physicians have difficulty when discussing Phase I clinical trials. Research demonstrates evidence of suboptimal communication. Little is known about communication strategies used by oncologists when recruiting patients for Phase I trials. We analyzed audio recorded Phase I consultations to identify oncologists' communication strategies. PATIENTS AND METHODS: Subjects were consecutive cancer patients from six medical oncologists attending one of three outpatient clinics at a major Cancer Center in the United States. Sixteen patients signed informed consent for audio recording of their consultations in which a Phase I study was discussed. These were transcribed in full and analyzed to identify communication strategies.
RESULTS: Six communication themes emerged from the analysis: (1) orienting, (2) educating patients, (3) describing uncertainty and prognosis, (4) persuading, (5) decision making, and (6) making a treatment recommendation. As expected, although there was some common ground between communication in Phase I and the Phase II and III settings, there were distinct differences.
CONCLUSIONS: Oncologists used persuasive communication, made explicit recommendations, or implicitly expressed a treatment preference and were choice limiting. This highlights the complexity of discussing Phase I trials and the need to develop strategies to aid oncologists and patients in these difficult conversations. Patient centered communication that values patient preferences while preserving the oncologist's agenda can be a helpful approach to these discussions.
Copyright © 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2010        PMID: 20878842     DOI: 10.1002/pon.1748

Source DB:  PubMed          Journal:  Psychooncology        ISSN: 1057-9249            Impact factor:   3.894


  24 in total

1.  Communicating about phase I trials: objective disclosures are only a first step.

Authors:  Anne Lederman Flamm; Rebecca D Pentz
Journal:  Oncologist       Date:  2012-04-04

2.  Identifying patient information needs about cancer clinical trials using a Question Prompt List.

Authors:  Richard F Brown; Elyse Shuk; Phyllis Butow; Shawna Edgerson; Martin H N Tattersall; Jamie S Ostroff
Journal:  Patient Educ Couns       Date:  2010-08-02

3.  Evaluation of an educational program to improve communication with patients about early-phase trial participation.

Authors:  Lesley J Fallowfield; Ivonne Solis-Trapala; Valerie A Jenkins
Journal:  Oncologist       Date:  2012-03-01

4.  Testing the utility of a cancer clinical trial specific Question Prompt List (QPL-CT) during oncology consultations.

Authors:  Richard F Brown; Carma L Bylund; Yuelin Li; Shawna Edgerson; Phyllis Butow
Journal:  Patient Educ Couns       Date:  2012-03-04

5.  Informed Consent and Decision Making Among Participants in Novel-Design Phase I Oncology Trials.

Authors:  Katherine E Reeder-Hayes; Megan C Roberts; Gail E Henderson; Elizabeth C Dees
Journal:  J Oncol Pract       Date:  2017-08-24       Impact factor: 3.840

6.  Do Patients With Advanced Cancer Have the Ability to Make Informed Decisions for Participation in Phase I Clinical Trials?

Authors:  Fay J Hlubocky; Greg A Sachs; Eric R Larson; Halla S Nimeiri; David Cella; Kristen E Wroblewski; Mark J Ratain; Jeffery M Peppercorn; Christopher K Daugherty
Journal:  J Clin Oncol       Date:  2018-07-09       Impact factor: 44.544

7.  Investigator Disclosure and Advanced Cancer Patient Understanding of Informed Consent and Prognosis in Phase I Clinical Trials.

Authors:  Fay J Hlubocky; Nancy E Kass; Debra Roter; Susan Larson; Kristen E Wroblewski; Jeremy Sugarman; Christopher K Daugherty
Journal:  J Oncol Pract       Date:  2018-05-22       Impact factor: 3.840

8.  Barriers to therapeutic clinical trials enrollment: differences between African-American and white cancer patients identified at the time of eligibility assessment.

Authors:  Lynne Penberthy; Richard Brown; Maureen Wilson-Genderson; Bassam Dahman; Gordon Ginder; Laura A Siminoff
Journal:  Clin Trials       Date:  2012-10-02       Impact factor: 2.486

9.  The bottleneck effect in lung cancer clinical trials.

Authors:  Luis E Gonzalez; Steven K Sutton; Christie Pratt; Matthew Gilbertson; Scott Antonia; Gwendolyn P Quinn
Journal:  J Cancer Educ       Date:  2013-09       Impact factor: 2.037

10.  Hope and persuasion by physicians during informed consent.

Authors:  Victoria A Miller; Melissa Cousino; Angela C Leek; Eric D Kodish
Journal:  J Clin Oncol       Date:  2014-09-08       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.